# ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia

> **NCT04256148** · PHASE2 · WITHDRAWN · sponsor: **Alexion Pharmaceuticals, Inc.**

## Conditions studied

- Warm Autoimmune Hemolytic Anemia

## Interventions

- **BIOLOGICAL:** ALXN1830
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04256148
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-07
- **Primary completion:** 2022-10-30
- **Final completion:** 2023-04-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study is withdrawn due to the global impact of the COVID-19 pandemic.
- **Last updated:** 2020-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04256148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04256148, "ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04256148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*